James D. Clark - 01 Apr 2023 Form 4 Insider Report for CVS HEALTH Corp (CVS)

Role
SVP, Cont & Chief Acct Officer
Signature
/s/ James D. Clark
Issuer symbol
CVS
Transactions as of
01 Apr 2023
Net transactions value
+$770,149
Form type
4
Filing time
04 Apr 2023, 16:26:05 UTC
Previous filing
01 Mar 2023
Next filing
04 Aug 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CVS Common Stock Tax liability $109,310 -1,471 -4.6% $74.31 30,457 01 Apr 2023 Direct F1
transaction CVS Common Stock (Restricted) Award $162,442 +2,186 +32% $74.31 9,080 01 Apr 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CVS Stock Option Award $717,017 +9,649 $74.31 9,649 01 Apr 2023 Common Stock 9,649 $74.31 Direct F11
holding CVS Stock Option 7,044 01 Apr 2023 Common Stock 7,044 $104.82 Direct F3
holding CVS Stock Option 9,050 01 Apr 2023 Common Stock 9,050 $78.05 Direct F4
holding CVS Stock Option 7,513 01 Apr 2023 Common Stock 7,513 $62.21 Direct F5
holding CVS Stock Option 24,240 01 Apr 2023 Common Stock 24,240 $54.19 Direct F6
holding CVS Stock Option 17,157 01 Apr 2023 Common Stock 17,157 $58.34 Direct F7, F8
holding CVS Stock Option 12,094 01 Apr 2023 Common Stock 12,094 $74.30 Direct F9
holding CVS Stock Option 6,756 01 Apr 2023 Common Stock 6,756 $101.09 Direct F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Surrender of shares in payment of withholding taxes due upon the vesting and settlement of a restricted stock unit award.
F2 Consists of restricted stock units awarded pursuant to Issuer's 2017 Incentive Compensation Plan. Restrictions lapse in four equal installments, commencing 4/1/2024.
F3 Options became exercisable in four equal annual installments beginning on 4/1/2017.
F4 Options became exercisable in four equal annual installments beginning on 4/3/2018.
F5 Options became exercisable in four equal annual installments, commencing 4/1/2019.
F6 Options became exercisable in four equal annual installments, commencing 4/1/2020.
F7 The number of shares subject to the option were calculated using a 30-day average price.
F8 Options became exercisable in four equal annual installments, commencing 4/1/2021.
F9 Option became exercisable in four equal annual installments, commencing 4/1/2022.
F10 Option became exercisable in four equal installments, commencing 4/1/2023.
F11 Option becomes exercisable in four equal annual installments, commencing 4/1/2024.